Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Decision on EU marketing authorisation expected for momelotinib by early 2024
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
Subscribe To Our Newsletter & Stay Updated